Research programme: prophylactic Chlamydia trachomatis vaccines - Genocea Biosciences
Alternative Names: Chlamydia vaccines - Genocea Biosciences; CT 144; CT 823; GEN-001; GENO 001Latest Information Update: 27 Mar 2023
At a glance
- Originator Genocea Biosciences; Harvard Medical School
- Developer Genocea Biosciences
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chlamydial infections
Most Recent Events
- 10 May 2022 Discontinued - Preclinical for Chlamydial infections (Prevention) in USA (Parenteral) (Genocea Biosciences website, March 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Chlamydial-infections(Prevention) in USA (Parenteral)
- 17 May 2018 Preclinical development is ongoing in USA (genocea Biosciences website, May 2018)